Notoginsenoside R1 Ameliorate High-Fat-Diet and Vitamin D3-Induced Atherosclerosis via Alleviating Inflammatory Response, Inhibiting Endothelial Dysfunction, and Regulating Gut Microbiota
Liying Ma,Yansong Gao,Ge Yang,Lei Zhao,Zijian Zhao,Yujuan Zhao,Yuhang Zhang,Shenhui Li,Shengyu Li
DOI: https://doi.org/10.2147/dddt.s451565
IF: 4.3188
2024-06-07
Drug Design Development and Therapy
Abstract:Liying Ma, 1, 2 Yansong Gao, 1 Ge Yang, 1 Lei Zhao, 2 Zijian Zhao, 1 Yujuan Zhao, 1 Yuhang Zhang, 2 Shenhui Li, 2 Shengyu Li 1 1 Institute of Agro-food Technology, Jilin Academy of Agricultural Sciences (Northeast Agricultural Research Center of China), Changchun, 130033, People's Republic of China; 2 School of Pharmaceutical Sciences, Changchun University of Chinese Medicine, Changchun, 130117, People's Republic of China Correspondence: Shengyu Li, Institute of Agro-Food Technology, Jilin Academy of Agricultural Sciences (Northeast Agricultural Research Center of China), No. 1363 Sheng-Tai Street, Changchun, Jilin Province, 130033, People's Republic of China, Tel +86 431 87063289, Fax +86 431 87063075, Email Aim: Natural medicines possess significant research and application value in the field of atherosclerosis (AS) treatment. The study was performed to investigate the impacts of a natural drug component, notoginsenoside R1, on the development of atherosclerosis (AS) and the potential mechanisms. Methods: Rats induced with AS by a high-fat-diet and vitamin D3 were treated with notoginsenoside R1 for six weeks. The ameliorative effect of NR1 on AS rats was assessed by detecting pathological changes in the abdominal aorta, biochemical indices in serum and protein expression in the abdominal aorta, as well as by analysing the gut microbiota. Results: The NR1 group exhibited a noticeable reduction in plaque pathology. Notoginsenoside R1 can significantly improve serum lipid profiles, encompassing TG, TC, LDL, ox-LDL, and HDL. Simultaneously, IL-6, IL-33, TNF-α, and IL-1β levels are decreased by notoginsenoside R1 in lowering inflammatory elements. Notoginsenoside R1 can suppress the secretion of VCAM-1 and ICAM-1, as well as enhance the levels of plasma NO and eNOS. Furthermore, notoginsenoside R1 inhibits the NLRP3/Cleaved Caspase-1/IL-1β inflammatory pathway and reduces the expression of the JNK2/P38 MAPK/VEGF endothelial damage pathway. Fecal analysis showed that notoginsenoside R1 remodeled the gut microbiota of AS rats by decreasing the count of pathogenic bacteria (such as Firmicutes and Proteobacteria ) and increasing the quantity of probiotic bacteria (such as Bacteroidetes ). Conclusion: Notoginsenoside R1, due to its unique anti-inflammatory properties, may potentially prevent the progression of atherosclerosis. This mechanism helps protect the vascular endothelium from damage, while also regulating the imbalance of intestinal microbiota, thereby maintaining the overall health of the body. Keywords: notoginsenoside R1, inflammation, endothelial damage, gut microbiota Graphical In China and worldwide, cardiovascular diseases (CVDs) are primary cause of fatalities, impairments, and a significant health burden. Atherosclerosis (AS), a chronic condition characterized by the buildup of lipids and fibrous substances in large arteries, plays a significant role in the onset and progression of CVDs. 1 Thus, preventing the development and advancement of AS could potentially reduce the mortality rate due to CVDs. Chronic inflammation theory, lipid infiltration theory, and endothelial injury theory have occupied important positions 2 in the study of the pathophysiological mechanisms of AS. It is subject to numerous factors, incorporating pathological mechanisms like inflammation, oxidative stress, apoptosis, and lipid buildup. 3 The features of AS primarily involve the participation of immunity and inflammation. Prolonged development of inflammation in the arterial intima leads to pathological changes in the aorta and triggers endothelial damage. 4 This ultimately results in the formation of plaques and increases plaque instability. 5 The development of AS is thought to coincide with flow-mediated inflammatory alterations in endothelial cells (ECs). Possible mechanisms of inflammation include cellular senescence, NLRP3 inflammasome activation, oxidative stress, increased intestinal permeability, and lifestyle and dietary effects on microbial composition. 6,7 Meanwhile, endothelial dysfunction also promotes rupture of atherosclerotic plaques. 8 Furthermore, growing research suggests that changes in the in the composition and function of intestinal microbiota can lead to disruptions in lipid metabolism and intestinal inflammation, which ultimately contribute to the initiation and advancement of AS. 9 Disturbances in intestinal microbiota and over colonization by harmful bacteria can damage the intestinal mucosa, disrupting its integrity and leading to greater permeability, which triggers an a -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal